These findings provide a rationale for the clinical testing of combination strategies with AR and UCHL1 inhibitors in Xp11.2 tRCC. This evidence concerns the gene UCHL1 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.